What are the side effects of hormone replacement therapy in women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Side Effects of Hormone Replacement Therapy in Women

Hormone replacement therapy carries well-documented serious risks including increased breast cancer, stroke, venous thromboembolism, coronary heart disease, and gallbladder disease, with the magnitude and timing of these harms varying by formulation and duration of use. 1, 2, 1

Major Cardiovascular and Thromboembolic Risks

The most concerning side effects involve cardiovascular and thromboembolic events:

  • Stroke: 8-11 additional cases per 10,000 woman-years (occurs with both estrogen-progestin and estrogen-only therapy) 1
  • Venous thromboembolism:
    • Deep venous thrombosis: 7-12 additional cases per 10,000 woman-years
    • Pulmonary embolism: 9 additional cases per 10,000 woman-years 1, 3
  • Coronary heart disease: 7 additional CHD events per 10,000 woman-years (primarily with estrogen-progestin) 1, 2

Critical timing consideration: Risks for venous thromboembolism, CHD, and stroke are highest within the first 1-2 years of therapy 1. This early risk window is particularly important for clinical decision-making.

Cancer Risks

Breast Cancer

  • 8 additional invasive breast cancers per 10,000 woman-years with estrogen-progestin therapy 1
  • Risk increases with longer-term use (appears to increase progressively with duration beyond 1-2 years) 1
  • Paradoxically, estrogen-only therapy may slightly reduce breast cancer risk in women with hysterectomy 4, 3

Endometrial Cancer

  • Unopposed estrogen dramatically increases endometrial cancer risk in women with intact uterus 1
  • This risk is largely eliminated when progestin is added for more than 10 days per cycle 5

Lung Cancer

  • While incidence may not increase, death from lung cancer increases (5 additional deaths per 10,000 woman-years with estrogen-progestin) 4, 3

Colorectal Cancer

  • Notably, this is actually a benefit: 6 fewer cases per 10,000 woman-years 1, 2

Other Significant Harms

  • Gallbladder disease/cholecystitis: 20-33 additional cases per 10,000 woman-years (higher with estrogen-only) 1, 3
  • Probable dementia: 22 additional cases per 10,000 woman-years (in women initiating therapy after age 65) 4, 3
  • Urinary incontinence: 872-1,271 additional cases per 10,000 woman-years (substantial increase) 3

Common but Less Serious Side Effects

Based on real-world data, 43% of women report side effects, with many experiencing multiple symptoms 6:

  • Weight gain: Most frequently reported (56.3% of those with side effects), though not definitively proven to be HRT-related 6
  • Side effects constitute the major reason for discontinuation in over half of women who stop therapy 6

Critical Risk Modifiers

Age and Time Since Menopause

The benefit-risk ratio fundamentally changes based on timing:

  • Favorable ratio: Women <60 years old OR within 10 years of menopause onset 7
  • Unfavorable ratio: Women >60 years old OR >10 years from menopause onset have greater absolute risks of CHD, stroke, thromboembolism, and dementia 1, 2, 7

Formulation Differences

  • Estrogen-progestin (combined therapy): Higher risks for breast cancer, CHD, and lung cancer mortality
  • Estrogen-only: Lower breast cancer risk but still carries stroke, thromboembolism, and gallbladder disease risks 1, 3

Common Pitfalls to Avoid

  1. Don't prescribe HRT for chronic disease prevention - The USPSTF explicitly recommends against routine use for preventing osteoporosis, heart disease, or other chronic conditions (Grade D recommendation) 2

  2. Don't initiate therapy in older women - Starting HRT in women >60 or >10 years post-menopause substantially increases absolute risk without proportional benefit 1, 7

  3. Don't forget progestin protection - Women with intact uterus require progestin or bazedoxifene to prevent endometrial cancer 8, 5

  4. Don't ignore individual risk factors - Women with factor V Leiden, obesity, prior thromboembolism, or cardiovascular risk factors face amplified risks 3

Evidence Quality Note

These recommendations are based primarily on high-quality randomized controlled trial data from the Women's Health Initiative (WHI), the largest and most rigorous studies of HRT 1, 2, 1, 3. The evidence for estrogen-progestin is stronger (fair to good) than for estrogen-only, which relies more on observational data 1.

When HRT is used for menopausal symptom relief (not chronic disease prevention), use the lowest effective dose for the shortest possible time, with periodic reevaluation of continued need 1, 2, 1, 7.

Related Questions

What is the recommended checklist before initiating hormone replacement therapy (HRT) in a perimenopausal woman?
In a woman who has completed Hodgkin lymphoma therapy and is in remission, with treatment‑induced menopause, how should hormone replacement therapy be initiated (including route, dosing, and need for progesterone based on uterine status) and what precautions are needed?
Should a woman under 60 years old, more than 10 years after surgical menopause following total hysterectomy, begin estrogen‑only hormone replacement therapy?
Can a patient discontinue hormone replacement therapy (HRT) abruptly?
What is the optimal timing and fasting requirement for collecting blood samples to assess a woman's hormone levels?
For a hospitalized medical patient with a Padua prediction score ≥ 4, how long should pharmacologic venous thromboembolism prophylaxis be given, and when should it be extended after discharge?
What are the criteria for diagnosing feeding problems in a newborn and the rationale for each criterion?
What dosing options are available for the olmesartan/hydrochlorothiazide fixed‑dose combinations (Olmesartan HCTZ or Micardis HCT)?
What are the side effects of estradiol?
What does elevated luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) indicate in a male, and what are the appropriate next steps for evaluation and management?
Is it safe to re‑irradiate a 41‑year‑old male with recurrent grade 2 IDH‑positive glioma (previously treated with surgery and 54 Gy in 30 fractions, brain‑stem maximum dose 53 Gy) using 40 Gy in 15 fractions, which would raise the brain‑stem dose to a maximum of 43 Gy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.